Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit

Article summary

Novartis beat Q3 adjusted earnings estimates despite a $1.9 billion Avidity impairment charge, lifted by strong sales of Kisqali, Kesimpta, and revised guidance.